Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response
BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.
You may also be interested in...
House Energy and Commerce members seek input as appropriate mix of incentives for next-generation, public-private ventures remains elusive.
House bipartisan legislators seek input as the appropriate mix of incentives for next-generation public-private ventures remains elusive.
Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements – provides the framework to mitigate against and respond to drug shortages.